Head and Neck

  • Rathan M. Subramaniam
  • J. M. Davison
  • Ujas Parikh
  • M. Abou-Zied
Part of the Medical Radiology book series (MEDRAD)


The hybrid technique of PET/CT has significantly impacted the imaging and management of head and neck squamous cell cancer (HNSCC) since its introduction and has become the technique of choice for imaging of this cancer. Diagnostic FDG PET/CT is useful for identification of an unknown primary tumor, delineation of extent of primary tumor, detection of regional lymph node involvement even in a normal-sized node, detection of distant metastases and occasional synchronous primary tumor, assessment of therapy response, and long-term surveillance for recurrence and metastases. The role of PET/CT is evolving in radiation therapy planning. Combined diagnostic PET/CT provides the best anatomic and metabolic in vivo information for the comprehensive management of HNSCC. FDG PET/CT is the modality of choice in detecting metastasis of differentiated thyroid cancer, when the disease is iodine negative. It is valuable in staging and prognosis of anaplastic and medullary thyroid cancer.


Thyroid Cancer Standardize Uptake Value Gross Tumor Volume Locoregional Control Metabolic Tumor Volume 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abraham T, Schoder H (2011) Thyroid cancer—indications and opportunities for positron emission tomography/computed tomography imaging. Semin Nucl Med 41(2):121–138PubMedCrossRefGoogle Scholar
  2. Andrade RS, Heron DE, Degirmenci B et al (2006) Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65(5):1315–1322PubMedCrossRefGoogle Scholar
  3. Been LB, Hoekstra HJ, Suurmeijer AJ, Jager PL, van der Laan BF, Elsinga PH (2009) [18F]FLT-PET and [18F]FDG-PET in the evaluation of radiotherapy for laryngeal cancer. Oral Oncol 45(12):e211–e215PubMedCrossRefGoogle Scholar
  4. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P (2004) Recombinant human thyrotropin stimulation of fluoro-d-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 89(1):91–95PubMedCrossRefGoogle Scholar
  5. Clavien PA, Heinrich S, Goerres GW et al (2005) Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242(2):235–243PubMedCrossRefGoogle Scholar
  6. Conti PS, Durski JM, Bacqai F, Grafton ST, Singer PA (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9(8):797–804PubMedCrossRefGoogle Scholar
  7. Dammann F, Horger M, Mueller-Berg M et al (2005) Rational diagnosis of squamous cell carcinoma of the head and neck region: comparative evaluation of CT, MRI, and 18FDG PET. AJR Am J Roentgenol 184(4):1326–1331PubMedGoogle Scholar
  8. Dibble E, Lara Alvarez A, Truong M, Mercier G, Cook E, Subramaniam R (2011) FDG Metabolic tumor volume and total glycolytic activity: prognostic imaging biomarkers of oral and oropharyngeal squamous cell cancers. J Nucl Med (in press)Google Scholar
  9. Dong MJ, Zhao K, Lin XT, Zhao J, Ruan LX, Liu ZF (2008) Role of fluorodeoxyglucose-PET versus fluorodeoxyglucose-PET/computed tomography in detection of unknown primary tumor: a meta-analysis of the literature. Nucl Med Commun 29(9):791–802PubMedGoogle Scholar
  10. Grunwald F, Menzel C, Bender H et al (1997) Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 7(3):327–335PubMedCrossRefGoogle Scholar
  11. Haerle SK, Schmid DT, Ahmad N, Hany TF, Stoeckli SJ (2011) The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol 47 (7):653–659Google Scholar
  12. Hendrickson K, Phillips M, Smith W, Peterson L, Krohn K, Rajendran J (2011) Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistance. Radiother Oncol 101(3):369–375Google Scholar
  13. La TH, Filion EJ, Turnbull BB et al (2009) Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys 74(5):1335–1341PubMedCrossRefGoogle Scholar
  14. Lee N, Nehmeh S, Schoder H et al (2009) Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 75(1):101–108PubMedCrossRefGoogle Scholar
  15. Machtay M, Natwa M, Andrel J et al (2009) Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck 31(2):195–201PubMedCrossRefGoogle Scholar
  16. Murphy JD, Chisholm KM, Daly ME et al (2011) Correlation between metabolic tumor volume and pathologic tumor volume in squamous cell carcinoma of the oral cavity. Radiother OncolGoogle Scholar
  17. Nanni C, Zamagni E, Farsad M et al (2006) Role of 18F-FDG PET/CT in the assessment of bone involvement in newly diagnosed multiple myeloma: preliminary results. Eur J Nucl Med Mol Imaging 33(5):525–531PubMedCrossRefGoogle Scholar
  18. Ong SC, Schoder H, Patel SG et al (2007) Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48(4):501–507PubMedCrossRefGoogle Scholar
  19. Poisson T, Deandreis D, Leboulleux S et al (2010) 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 37(12):2277–2285PubMedCrossRefGoogle Scholar
  20. Pryma DA, Schoder H, Gonen M, Robbins RJ, Larson SM, Yeung HW (2006) Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer patients. J Nucl Med 47(8):1260–1266PubMedGoogle Scholar
  21. Rischin D, Hicks RJ, Fisher R et al (2006) Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 24(13):2098–2104PubMedCrossRefGoogle Scholar
  22. Rusthoven K, Koshy M, Paulino A (2004) The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101(11):2641–2649PubMedCrossRefGoogle Scholar
  23. Schwartz DL, Ford E, Rajendran J et al (2005) FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61(1):129–136Google Scholar
  24. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJ, Kaanders JH (2010). 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med 51(6):866–874Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Rathan M. Subramaniam
    • 3
    • 1
  • J. M. Davison
    • 1
  • Ujas Parikh
    • 1
  • M. Abou-Zied
    • 2
  1. 1.Boston University School of MedicineBostonUSA
  2. 2.Department of Nuclear MedicineState University of New York at BuffaloBuffaloUSA
  3. 3.Russell H Morgan Departments of Radiology and Radiological Sciences InstitutionsThe Johns Hopkins Medical InstitutionsBaltimore USA

Personalised recommendations